H. B. Muss

814 citations

28 papers · 636 indexed · h-index 13

Oncology top 10%
- Cancer Treatment and Pharmacology 9
Cancer Research top 10%
- Breast Cancer Treatment Studies 9
Obstetrics and Gynecology top 10%
- Endometrial and Cervical Cancer Treatments 2
Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment 2
Genetics top 10%
- Estrogen and related hormone effects 9
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 6
Surgery
- Nausea and vomiting management 2
- Anesthesia and Pain Management 2

Co-authors: J. N. Ingle L. E. Shepherd Michael Palmer Silvana Martino Nicholas J. Robert Dongsheng Tu Frederick Richards Joseph L. Pater
Cited by: Oncology Cancer Research Obstetrics and Gynecology
Journals: New England Journal of Medicine (1 paper)Journal of Clinical Oncology (18 papers)JNCI Journal of the National Cancer Institute (2 papers)
Partner nations: United States Canada Belgium

In The Last Decade

H. B. Muss

26 papers receiving 616 citations

Peers

Countries citing papers authored by H. B. Muss

Since Specialization

Citations

This map shows the geographic impact of H. B. Muss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. B. Muss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. B. Muss more than expected).

Fields of papers citing papers by H. B. Muss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. B. Muss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. B. Muss. The network helps show where H. B. Muss may publish in the future.

Co-authorship network

The 25 scholars most cited alongside H. B. Muss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. B. Muss Line = papers co-authored together H. B. Muss links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cerebral Folate Deficiency, Autism, and the Role of Leucovorin New England Journal of Medicine ·I David Goldman,H. B. Muss	2026	0
2	P16^INK4aexpression after chemotherapy in older women with early-stage breast cancer. Journal of Clinical Oncology ·H. B. Muss,Jairam Krishnamurthy,Shani Alston,Aidan Lacy,Trevor A. Jolly,Geraint P. Williams,Lisa A. Carey,E. Claire Dees,CK Anders,William Irvin,N. E. Sharpless	2011	6
3	The relationship between age and survival outcomes for eribulin in metastatic breast cancer. Journal of Clinical Oncology ·C.J. Twelves,Linda T. Vahdat,Javier Cortés,J. Wanders,CE Dutcus,Seth Seegobin,H. B. Muss	2011	5
4	Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. Journal of Clinical Oncology ·Dennis C. Sgroi,Erin Carney,Elizabeth Richardson,L. Steffel,Shemeica Binns,Daniel Finkelstein,L. E. Shepherd,N. C. Kesty,Catherine A. Schnabel,Mark G. Erlander,James N. Ingle,Peggy L. Porter,Soonmyoung Paik,H. B. Muss,K. Pritchard,Dongsheng Tu,Paul E. Goss	2011	2
5	Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer JNCI Journal of the National Cancer Institute ·J-AW Chapman,D. Meng,L. E. Shepherd,W.R. Parulekar,J. N. Ingle,H. B. Muss,Michael Palmer,C. Yu,P. E. Goss	2008	135
6	Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 Journal of Clinical Oncology ·H. B. Muss,DA Berry,C. Cirrincione,Maria Theodoulou,Ann M. Mauer,HJ Cohen,A. H. Partridge,Larry Norton,C. Hudis,Eric P. Winer,(unknown)	2008	19
7	Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy Journal of Clinical Oncology ·Steven M. Grunberg,Margaret Dugan,H. B. Muss,M. L. B. WOOD,Susan Burdette-Radoux,Tracey Weisberg	2007	5
8	Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients Journal of Clinical Oncology ·J. W. Chapman,D. Meng,L. E. Shepherd,W.R. Parulekar,J. N. Ingle,H. B. Muss,Michael Palmer,Chi‐Chang Yu,P. E. Goss	2007	1
9	Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience Journal of Clinical Oncology ·H. B. Muss,DA Berry,C. Cirrincione,Daniel Budman,I. Craig Henderson,M. Citron,Larry Norton,EP Winer,Clifford A. Hudis	2006	0
10	Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Journal of Clinical Oncology ·Paul E. Goss,J. N. Ingle,Silvana Martino,Nicholas J. Robert,H. B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,L. E. Shepherd,Joseph L. Pater	2004	63
11	Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen Journal of Clinical Oncology ·Timothy J. Whelan,Paul E. Goss,J. N. Ingle,Joseph L. Pater,Lois E. Shepherd,Michael Palmer,Dongsheng Tu,Nicholas J. Robert,Silvana Martino,H. B. Muss	2004	12
12	Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients Journal of Clinical Oncology ·David Warr,Peter D. Eisenberg,Paul J. Hesketh,Richard J. Gralla,H. B. Muss,H. Raftopolous,M. Gabriel,A. Rodgers,Carolyn M. Hustad,Franck Skobieranda	2004	1
13	Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group Journal of Clinical Oncology ·Marcus E. Randall,Giacoma Maria Floriana Brunetto,H. B. Muss,R. S. Mannel,NM Spirtos,Foley Jeffrey,J.T. Thigpen,J Bénda	2003	51
14	Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. Journal of Clinical Oncology ·Joseph Aisner,C. Cirrincione,Michael Perloff,Michael C. Perry,Daniel R. Budman,Jeffrey S. Abrams,Lawrence Panasci,H. B. Muss,Marc L. Citron,(unknown)	1995	29
15	5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Epithelial Ovarian Carcinoma American Journal of Clinical Oncology ·Katherine Y. Look,John A. Blessing,H. B. Muss,Koen DeGeest	1992	11
16	5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Squamous Cell Carcinoma of the Cervix American Journal of Clinical Oncology ·Katherine Y. Look,John A. Blessing,H. B. Muss,Edward E. Partridge,John H. Malfetano	1992	13
17	Differences Between Black and White Women With Breast Cancer in Time From Symptom Recognition to Medical Consultation JNCI Journal of the National Cancer Institute ·Ralph J. Coates,Diana D. Bransfield,Margaret Wesley,Benjamin F. Hankey,J. William Eley,Raymond S. Greenberg,Dana Flanders,Carrie P. Hunter,B. K. Edwards,M. Forman,V. W. Chen,Peggy Reynolds,Peggy Boyd,D. Austin,H. B. Muss,Robert S. Blacklow,(unknown)	1992	100
18	Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. PubMed ·Bayard L. Powell,Robert L. Capizzi,H. B. Muss,James D. Bearden,Evan Lyerly,Daryl Rosenbaum,Timothy M. Morgan,Frederick Richards,Don V. Jackson,Dougľas R. White	1989	38
19	Improvement of long-term survival in extensive small-cell lung cancer. Journal of Clinical Oncology ·Don V. Jackson,L. Douglas Case,Patricia J. Zekan,Bob Powell,R D Caldwell,James D. Bearden,Eric C. Nelson,H. B. Muss,M. R. Cooper,Frederick Richards	1988	35
20	Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. Journal of Clinical Oncology ·H. B. Muss,L R Smith,M. Robert Cooper	1987	23

About H. B. Muss

H. B. Muss is a scholar working on Cancer Research, Oncology and Genetics, having authored 28 papers that have together received 636 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (6 papers), Nausea and vomiting management (2 papers), Anesthesia and Pain Management (2 papers), Endometrial and Cervical Cancer Treatments (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). The work is most often cited by research in Oncology (380 citations), Cancer Research (200 citations) and Obstetrics and Gynecology (67 citations). H. B. Muss has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include J. N. Ingle, L. E. Shepherd, Michael Palmer, Silvana Martino, Nicholas J. Robert, Dongsheng Tu, Frederick Richards, Joseph L. Pater, M. Robert Cooper and Don V. Jackson. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact